References
- Cobleigh M. A., Berris R. F., Bush T., Davidson W. E., Robert N. J., Sparano J. A., Tormey D. C., Wood W. C. Estrogen replacement therapy in breast cancer survivors: a time for change. J. Am. Med. Assoc 1994; 272: 540–5
- Haddow A., Watkinson J. M., Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. Br. Med. J. 1944; 23: 393–8, September
- Clarke C. L., Sutherland R. L. Progestin regulation of cellular proliferation. Endocr. Rev. 1990; 11: 266–301
- Persson I., Yuen J., Bergkvist L., Adami H-O., Hoover R., Schairer C. Combined oestrogen-progestin replacement and breast cancer risk. Lancet 1992; 340: 1044
- Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int. J. Cancer 1988; 42: 832–8
- Rose C., Mouridsen H. T. Endocrine management of advanced breast cancer. Horm. Res. 1989; 32(Suppl. 1)189–97, )
- Eden J. A. Oestrogen and the breast. 1. Myths about oestrogen and breast cancer. Med. J. Aust. 1992; 157: 175–7
- Eden J. A., Bush T., Nand S., Wren B. G. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995; 2: 67–72
- Bulbrook R. D., Leake R. E., George W. D. Oestrogens in the initiation and promotion of breast cancer. Oestrogen and the Human Breast , J. S. Beck. Royal Society of Edinburgh, edinburgh 1989; 67–76, (
- Musgrove E. A., Lee C. S. L., Sutherland R. L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor-a, epidermal growth factor receptor,c-fos, c-myc genes. Mol. Cell Biol 1991; 11: 5032–43
- Clarkson T. B., Anthony M. S., Hughes C. L., Jr. Estrogenic soybean isoflavones and chronic disease: risks and benefits. Trends Endocrinol. Metab. 1995; 6: 11–16
- Anderson J. W., Johnstone B. M., Cook-Newell M. E. Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 1995; 333: 276–82